Who Owns Entrada Therapeutics Stock?
NASDAQ: TRDAHealthcareBiotechnologyUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 82.11%
- Held by insiders
- 12.23%
- Institutional holders
- 181
- Institutions 82.1%
- Insiders 12.2%
- Public and other 5.7%
Who owns Entrada Therapeutics stock?
Institutional investors own about 82.1% of Entrada Therapeutics's shares, spread across 181 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 12.23% of TRDA.
The largest institutional holders are Baker Bros. Advisors, LP (13.03%), 5AM Venture Management, LLC (10.42%) and Blackrock Inc. (6.63%). Together, the top 10 institutions control 50.1% of shares outstanding. In their latest filings, 4 of the top 10 institutions increased their TRDA positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of TRDA
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Baker Bros. Advisors, LP | 5.07M | 13.03% | 0.0% |
| 5AM Venture Management, LLC | 4.06M | 10.42% | 0.0% |
| Blackrock Inc. | 2.58M | 6.63% | +9.5% |
| Merck & Co., Inc. | 1.74M | 4.47% | 0.0% |
| Vanguard Capital Management LLC | 1.27M | 3.26% | +1.1% |
| MPM Bioimpact LLC | 1.25M | 3.22% | +100.0% |
| TCG Crossover Management, LLC | 1.06M | 2.72% | -53.6% |
| Wellington Management Group, LLP | 954.42K | 2.45% | -7.8% |
| Millennium Management Llc | 763.96K | 1.96% | +47.1% |
| StepStone Group LP | 761.28K | 1.96% | 0.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of TRDA
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 953.73K | 2.45% |
| iShares Trust-iShares Russell 2000 ETF | 756.49K | 1.94% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 322.23K | 0.83% |
| T. Rowe Price Health Sciences Fund, Inc. | 295.98K | 0.76% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 283.04K | 0.73% |
| iShares Trust-iShares Russell 2000 Value ETF | 268.14K | 0.69% |
| iShares Trust-iShares Biotechnology ETF | 197.06K | 0.51% |
| JPMorgan Trust I-JPMorgan U.S. Small Company Fund | 175.41K | 0.45% |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 145.78K | 0.37% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 116.75K | 0.30% |
Frequently asked questions
Who is the largest shareholder of Entrada Therapeutics?
Baker Bros. Advisors, LP is the largest institutional shareholder of TRDA, owning 13.03% of shares outstanding (5.07M shares) as of its latest 13F filing.
What percentage of Entrada Therapeutics is owned by institutions?
Institutions own about 82.1% of TRDA shares and 93.6% of the public float.
How much of Entrada Therapeutics do insiders own?
Insiders, such as officers and directors, own about 12.23% of TRDA shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.